{"&cites=14370914940926626173&as_sdt=2005&sciodt=0,5&hl=en":[{"title":"Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a …","url":"https://www.sciencedirect.com/science/article/pii/S1470204519304139","authors":["RJ Motzer","RJ Motzer BI Rini","RJ Motzer BI Rini DF McDermott","RJ Motzer BI Rini DF McDermott OA Frontera…"],"year":2019,"numCitations":99,"pdf":"https://researchers.mq.edu.au/en/publications/nivolumab-plus-ipilimumab-versus-sunitinib-in-first-line-treatmen","citationUrl":"http://scholar.google.com/scholar?cites=6021365036904200257&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:QbihN5kvkFMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6021365036904200257&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier","p":1,"exp":1596898396135},{"title":"A view on drug resistance in cancer","url":"https://www.nature.com/articles/s41586-019-1730-1","authors":["N Vasan","N Vasan J Baselga","N Vasan J Baselga DM Hyman"],"year":2019,"numCitations":75,"citationUrl":"http://scholar.google.com/scholar?cites=11503968076933486984&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:iNkN7QNOpp8J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=11503968076933486984&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Updated European Association of Urology guidelines on renal cell carcinoma: immune checkpoint inhibition is the new backbone in first-line treatment of metastatic …","url":"https://www.sciencedirect.com/science/article/pii/S0302283819304269","authors":["L Albiges","L Albiges T Powles","L Albiges T Powles M Staehler","L Albiges T Powles M Staehler K Bensalah","L Albiges T Powles M Staehler K Bensalah RH Giles…"],"year":2019,"numCitations":48,"pdf":"https://www.researchgate.net/profile/Thomas_Lam5/publication/333671322_Updated_European_Association_of_Urology_Guidelines_on_Renal_Cell_Carcinoma_Immune_Checkpoint_Inhibition_Is_the_New_Backbone_in_First-line_Treatment_of_Metastatic_Clear-cell_Renal_Cell_Carcinoma/links/5cfd92d392851c874c5b4fc7/Updated-European-Association-of-Urology-Guidelines-on-Renal-Cell-Carcinoma-Immune-Checkpoint-Inhibition-Is-the-New-Backbone-in-First-line-Treatment-of-Metastatic-Clear-cell-Renal-Cell-Carcinoma.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1736679606747912938&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:6trfqObsGRgJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1736679606747912938&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"Towards individualized therapy for metastatic renal cell carcinoma","url":"https://www.nature.com/articles/s41571-019-0209-1","authors":["RR Kotecha","RR Kotecha RJ Motzer","RR Kotecha RJ Motzer MH Voss"],"year":2019,"numCitations":26,"citationUrl":"http://scholar.google.com/scholar?cites=14400902405870945540&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:BIUBW3BI2scJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=14400902405870945540&hl=en&as_sdt=2005&sciodt=0,5","publication":"nature.com"},{"title":"Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas …","url":"https://www.sciencedirect.com/science/article/pii/S1470204519304589","authors":["RS Herbst","RS Herbst HT Arkenau","RS Herbst HT Arkenau R Santana"],"year":2019,"numCitations":27,"citationUrl":"http://scholar.google.com/scholar?cites=1017422728817139702&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:9t-N0ZScHg4J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1017422728817139702&hl=en&as_sdt=2005&sciodt=0,5","publication":"Elsevier"},{"title":"The intersection between tumor angiogenesis and immune suppression","url":"https://clincancerres.aacrjournals.org/content/25/18/5449.abstract","authors":["OE Rahma","OE Rahma FS Hodi"],"year":2019,"numCitations":22,"citationUrl":"http://scholar.google.com/scholar?cites=6140166113107344266&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:inunQYxANlUJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=6140166113107344266&hl=en&as_sdt=2005&sciodt=0,5","publication":"AACR"},{"title":"Combination therapy as first-line treatment in metastatic renal-cell carcinoma","url":"https://www.nejm.org/doi/full/10.1056/NEJMe1900887","authors":["B Escudier"],"year":2019,"numCitations":19,"citationUrl":"http://scholar.google.com/scholar?cites=969670948256617057&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:YRLaA5f2dA0J:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=969670948256617057&hl=en&as_sdt=2005&sciodt=0,5","publication":"Mass Medical Soc"},{"title":"Renal cell carcinoma","url":"http://nuf.nu/NoRenCa/EAU-Guidelines-on-Renal-Cell-Carcinoma-2019.pdf","authors":["B Ljungberg","B Ljungberg K Bensalah","B Ljungberg K Bensalah A Bex","B Ljungberg K Bensalah A Bex S Canfield…"],"year":2015,"numCitations":18,"pdf":"http://nuf.nu/NoRenCa/EAU-Guidelines-on-Renal-Cell-Carcinoma-2019.pdf","citationUrl":"http://scholar.google.com/scholar?cites=1511057121375948271&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:7w3wKnJa-BQJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=1511057121375948271&hl=en&as_sdt=2005&sciodt=0,5","publication":"nuf.nu"},{"title":"Current perspectives in cancer immunotherapy","url":"https://www.mdpi.com/2072-6694/11/10/1472","authors":["T Christofi","T Christofi S Baritaki","T Christofi S Baritaki L Falzone","T Christofi S Baritaki L Falzone M Libra","T Christofi S Baritaki L Falzone M Libra A Zaravinos"],"year":2019,"numCitations":24,"pdf":"https://www.mdpi.com/2072-6694/11/10/1472/pdf","citationUrl":"http://scholar.google.com/scholar?cites=16423617146517613083&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:G2oyWcdo7OMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16423617146517613083&hl=en&as_sdt=2005&sciodt=0,5","publication":"mdpi.com"},{"title":"Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies","url":"https://ascopubs.org/doi/abs/10.1200/EDBK_237987","authors":["M Datta","M Datta LM Coussens","M Datta LM Coussens H Nishikawa…"],"year":2019,"numCitations":21,"pdf":"https://ascopubs.org/doi/pdfdirect/10.1200/EDBK_237987","citationUrl":"http://scholar.google.com/scholar?cites=16361997058942509138&as_sdt=2005&sciodt=0,5&hl=en","relatedUrl":"http://scholar.google.com/scholar?q=related:UiBBsqJ9EeMJ:scholar.google.com/&scioq=&hl=en&as_sdt=2005&sciodt=0,5","urlVersionsList":"http://scholar.google.com/scholar?cluster=16361997058942509138&hl=en&as_sdt=2005&sciodt=0,5","publication":"ascopubs.org"}]}